NIH R01 · 2025
Alleviation of chemotherapy-induced cardiovascular toxicity
ABSTRACT Many cancer drugs increase cardiovascular (CV) events, including hypertension, thrombosis, and cardiomyopathy. Damaged endothelial cells (ECs) caused by chemotherapy can trigger the development and progression of cardiovascular disease (CVD). ECs represent a critical target for improving the management of chemotherapy-induced CV toxicity. The lysosomal pathway is critical to maintaining EC homeostasis. However, the role of lysosomes in chemotherapy-induced EC dysfunction and whether rescuing lysosomal function is a potential strategy to treat CV toxicity remain to be fully explored. Our preliminary data suggest that the chemotherapeutic drug doxorubicin (DOX) impairs lysosomal…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.